.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint calls for introduction of patients along with MASLD as well as measurement of liver results in cardio-- renal-- metabolic trials, when data recommend mechanistically possible perks as well as clinical safety-- and lays out factors for test design as well as governing approval.